ℹ️ Click on the Information button on the figure below to learn more
 
 

The HTA process aims to support healthcare policy decisions. During this stage, the information gathered and assessed by the HTA body is appraised by decision-makers (e.g., ministries of health, appointed committees, etc.).

The decision-making process can impact the HTA process. For example, if decisions are appealable, the HTA body may be asked to conduct further analysis. If decisions involve an expert committee, the HTA body may need to coordinate the committee or attend its meetings. HTA reports may be confidential or open for public comment.

Beyond recommendations

Recommendations about whether a product can be made available within a healthcare system may be seen as rigid, lacking flexibility for those needing new therapies. Since these recommendations are often population-focused, they may not allow for individual exceptions. To address this, HTA bodies use alternative mechanisms that offer more flexibility.

  • Coverage with evidence development (CED): This allows access to promising products that lack sufficient data on clinical or cost-effectiveness. HTA can recommend the use of such products, provided there is formal evidence collection, such as through a registry or ongoing clinical trials required by regulatory authorities to gather further evidence.

  • Price determination: The price of a health technology affects access for both providers and patients. In some cases, payers may negotiate with the company based on the perceived value of the technology, especially when it's useful for specific cases. HTA bodies may or may not be involved in this process. Value-based pricing can be challenging as it is difficult to capture all aspects of value, such as convenience or improved methods of delivery.

  • Decision aids and clinical guidelines: HTA may recommend that a product is most beneficial when used in specific patient groups or after certain treatments. To maximize its value, payers may reimburse the medicine in conjunction with clinical guidelines or decision aids. Decision aids help patients and clinicians make informed choices by weighing the risks and benefits of different treatments. These tools can guide conversations about the best treatment options based on individual values and preferences. Read an example from a hospital that shows how such a decision aid might look.

  • Health system priority setting and budgets: HTA information is used to determine which services should be funded, aiming to provide value within the constraints of a healthcare budget. The method known as Program Budgeting and Marginal Analysis is employed to identify the optimal mix of services that balance value and affordability.

Dissemination

The dissemination of findings and recommendations, as well as monitoring impact, may be handled by a separate organisation rather than the HTA body itself.

An HTA report often needs to be communicated to those unfamiliar with clinical research or economic evaluation. Depending on the HTA body's structure and its relationship with decision-makers, the report may be delivered in various formats—such as print or face-to-face presentations—and may or may not require peer review. The presentation style and technical language used will vary based on whether the audience is a committee of experts or a decision-maker.

Implementation and impact

When decision-makers reach a conclusion based on an HTA report, that decision is meant to be implemented and will impact the population. The HTA body's appraisal process should consider the implementation and its effects. Additionally, a feedback loop may be in place to measure the impact of HTA recommendations on the population, informing future decisions.